ABLYNX RECEIVES ?1.2 MILLION GRANT TO FURTHER ADVANCE ITS ANTI-IL-6R PROGRAMME, ALX-0061

(Thomson Reuters ONE) -


GHENT, Belgium, 19 February 2010- Ablynx [Euronext Brussels: ABLX], announced
today that it has been awarded a grant worth ?1.2 million by the Flemish agency
for Innovation by Science and Technology (IWT).

The grant supports Ablynx in accelerating the development of its Nanobody-based
programme, ALX-0061, into clinical development for the treatment of autoimmune
and inflammatory diseases.

ALX-0061 binds to the IL-6 receptor (IL-6R). It has a high potency and
demonstrated a favourable pharmacodynamic (PD), pharmacokinetic (PK) and safety
profile in pre-clinical testing compared with the benchmark molecule. ALX-0061
has no Fc-mediated effector function which may translate into an improved safety
profile. Due to its monovalent binding to the target, it also does not have the
potential to crosslink the IL-6R target which may have some benefits compared
with monoclonal antibody approaches.

Edwin Moses, CEO and Chairman of Ablynx, said:

"ALX-0061 is a key programme in the Ablynx portfolio and Ablynx is on track to
file an IND equivalent in Europe before the end of this year. We are delighted
with IWT's continued support of the Nanobody platform and very pleased we will
also receive support for our preclinical and clinical activities related to
ALX-0061. This grant is a valuable contribution to the ALX-0061 programme, which
we are advancing towards clinical development. There are already four Nanobodies
in the clinic, with our lead programme, ALX-0081, a novel anti-thrombotic, in
Phase II since September 2009."

-ends-

For more information, please contact:

College Hill Life Sciences - for International media enquiries:
Sue Charles, Justine Lamond
t:   +44 (0)20 7866 7857
f:   +44 (0)20 7866 7900
e:  ablynx(at)collegehill.com

Ablynx:
Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e:  edwin.moses(at)ablynx.com

Eva-Lotta Allan
Chief Business Officer
t:   +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 /
    +44 (0)7990 570 900
e:  eva-lotta.allan(at)ablynx.com



[HUG#1386741]





Complete version of the press release: http://hugin.info/137912/R/1386741/345289.pdf

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 19.02.2010 - 18:01 Uhr
Sprache: Deutsch
News-ID 12752
Anzahl Zeichen: 0

contact information:
Town:

Ghent

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 161 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"ABLYNX RECEIVES ?1.2 MILLION GRANT TO FURTHER ADVANCE ITS ANTI-IL-6R PROGRAMME, ALX-0061"
steht unter der journalistisch-redaktionellen Verantwortung von

Ablynx (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regar ...

GHENT, BELGIUM -- (Marketwired) -- 08/27/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to tr ...

Ablynx Announces Half-Year Results for 2013 ...

GHENT, BELGIUM -- (Marketwired) -- 08/21/13 -- (EURONEXT BRUSSELS: ABLX) today announced its results for the six-month period ending 30 June 2013, which have been prepared in accordance with the IAS 34 "Interim Financial Reporting" as adop ...

Ablynx Announces Warrant Exercise ...

GHENT, BELGIUM -- (Marketwired) -- 07/23/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 273,913 common shares have been issued by the ...

Alle Meldungen von Ablynx